Events

Rappel de i-STAT Kaolin ACT Cartridges

Selon New Zealand Medicines and Medical Devices Safety Authority, ce/cet/cette rappel concerne un dispositif en/au/aux/à New Zealand qui a été fabriqué par Abbott Point of Care Canada Ltd.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    22423
  • Date de mise en oeuvre de l'événement
    2018-01-11
  • Pays de l'événement
    New Zealand
  • Source de l'événement
    NZMMDSA
  • URL de la source de l'événement
    https://medsafe.govt.nz/hot/Recalls/RecallSearch.asp
  • Notes / Alertes
    Data from New Zealand is current through July 2018. All of the data comes from the New Zealand Medicines and Medical Devices Safety Authority, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and New Zealand.
  • Notes supplémentaires dans les données
    Recalling Organisation: Abbott Australasia Pty Ltd (NZ), Abbott Laboratories NZ, 4 Pacific Rise, Mt Wellington, Auckland 1060
  • Cause
    To regards to the drug aprotinin (trasylol), which was previously withdrawn from many markets but may be available in some countries/regions. internal studies, have identified that the i-stat kaolin act test may be prolonged immediately after the administration of an initial full dose aprotinin bolus of 400 kallikrein inhibitor units (kiu)/ml. once the drug has fully distributed throughout the body there is no impact on the act result reported. for aprotinin, 200-280 kiu/ml is considered a therapeutic or steady state concentration during cpb.
  • Action
    Manufacturer to issue advice regarding use

Device

i-STAT Kaolin ACT Cartridges

Manufacturer

Abbott Point of Care Canada Ltd
  • Société-mère du fabricant (2017)
    Abbott Laboratories
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    NZMMDSA